Ambulatory blood pressure (ABP) monitoring is recommended as a standard method for the evaluation of resistant hypertension (RH). This study assessed the diagnostic value of home blood pressure (HBP) monitoring in RH. Subjects on stable treatment with X3 antihypertensive drugs were included. Clinic RH (CRH) was defined as elevated clinic blood pressure and true RH (TRH) as elevated ABP. The diagnosis of CRH was verified by ABP and HBP monitoring. The diagnostic value of HBP was assessed by taking ABP as reference method. Threshold for hypertension diagnosis was X135/85 mm Hg (systolic and/or diastolic) for HBP and awake ABP and X140/90 mm Hg for clinic blood pressure. Among 73 subjects on X3 antihypertensive drugs, 44 (60%) had CRH and 40 (55%) TRH. There was agreement between ABP and HBP in diagnosing CRH in 82% of the cases (26 subjects (59%) with CRH and 10 (23%) without CRH; kappa 0.59). Regarding the diagnosis of TRH, there was agreement between ABP and HBP in 74% of the cases (36 subjects (49%) with TRH and 18 (25%) without TRH; kappa 0.46). The sensitivity, specificity, and positive and negative predictive values of HBP in detecting CRH were 93%, 63%, and 81% and 83%, respectively, and TRH were 90%, 55%, and 71%, and 82%, respectively (ABP taken as reference method). These data suggest that HBP is a reliable alternative to ABP in the evaluation of RH. These methods are necessary in both uncontrolled and controlled subjects on triple therapy to detect the white coat phenomenon and also masked RH. ( Although the exact prevalence of RH is unknown, clinical trials suggest that it affects 20 --30% of participants 1 and is related with worse prognosis than subjects with controlled hypertension.
INTRODUCTION

Resistant hypertension (RH) remains a common clinical issue.
Although the exact prevalence of RH is unknown, clinical trials suggest that it affects 20 --30% of participants 1 and is related with worse prognosis than subjects with controlled hypertension. 1, 2 Studies have shown that a significant white-coat effect is as common in patients with RH as in the general hypertensive population, with prevalence ranging from 20 to 30%. 1, 3 Furthermore, using only conventional clinic blood pressure (CBP) measurements as follow-up method, patients with masked RH 4 cannot be detected, antihypertensive treatment is not up-titrated and blood pressure (BP) control is not achieved. Several studies have shown that ambulatory BP (ABP) is superior to clinical measurements in predicting hypertension-induced target-organ damage and cardiovascular events in patients with RH. 2, 5 Therefore, current guidelines recommend ABP monitoring as a standard method for the evaluation of RH. 1, 6 Home BP (HBP) monitoring has also been shown to predict cardiovascular events better than clinical measurements 7, 8 and several studies have reported similar ability of HBP with ABP in diagnosing white coat, masked and sustained hypertension. 9 Previous studies have also shown that HBP and ABP monitoring are interchangeable diagnostic methods, not only in untreated but also in treated hypertensives. 9 --11 However, in patients with RH, although the clinical utility of ABP has been documented, to date the usefulness of HBP monitoring has not been investigated.
This study assessed the diagnostic value of HBP monitoring in the evaluation of subjects with RH by taking ABP monitoring as reference method.
METHODS
Study design
A database including BP values, anthropometric characteristics, treatment details and medical history was developed in the context of eight previous prospective clinical trials conducted from 1994 to 2007. Participants were consecutive adults attending a university hospital hypertension clinic, untreated or on stable antihypertensive treatment for X4 weeks. They were invited to participate in trials that involved measurements of CBP, HBP and ABP using a standard protocol for each measurement method as described below. In each participant, all BP measurements were performed within 6 weeks. Exclusion criteria were severe renal, cardiac or other systemic disease, sustained arrhythmia and evidence of secondary hypertension. Subjects with RH were identified from the above database by applying the definitions of clinic RH (CRH) and true RH (TRH) as mentioned below. The protocol of the present study was approved by the hospital scientific committee, which did not require individual patients' informed consent for the analysis of the BP values and the retrospective collection of other data from patients' records.
BP measurements
HBP was monitored on six routine working days within 2 weeks 12 using validated oscillometric arm devices Omron 705IT (Omron Healthcare Europe BV, Hoofddorp, The Netherlands, inflatable bladder 13 Â 23 or 15 Â 30 cm according to the individual's arm circumference), Omron HEM-705CP (Omron Healthcare Europe BV, inflatable bladder size 12 Â 23 or 14 Â 28 cm according to the individual's arm circumference) or Omron IC (Omron Healthcare Europe BV, bladder 12 Â 23 and 14 Â 28 cm).
use of the devices. They were instructed to take duplicate morning (0600 --1000 hours, before drug intake if treated) and evening (1800 --2200 h) measurements after 5 min sitting rest and with 1 min interval between measurements. A form was supplied to the participants to report all their HBP readings, which were also printed by the device memory (Omron HEM-705CP) or downloaded through a computer link (Omron 705IT and Omron IC).
ABP was monitored using validated oscillometric devices SpaceLabs 90207 or 90217 (SpaceLabs Inc., Redmond, WA, USA, bladder size 12 Â 23 or 14 Â 30 cm where appropriate).
14, 15 The devices were programmed to measure BP at 20-min intervals for 24 h and were applied on a routine working day. Subjects were instructed to follow their usual daily activities but to avoid extreme physical activities and to remain still with the forearm extended during each BP reading. A brief diary was provided to report the time when they went to bed and arose. Before each HBP or ABP monitoring session, the accuracy of the devices was tested in each individual against a standard mercury sphygmomanometer (three successive readings; Y connector) to ensure that there was no consistent difference of 410 mm Hg in measured BP.
CBP was measured in two study visits, before and between or after HBP and ABP monitoring. CBP measurement in a pre-study visit was also available for the total of participants. Triplicate BP measurements were taken at each clinic visit after 5 min sitting rest and with at least 1 min between recordings using a standard mercury sphygmomanometer (bladder 12 Â 23 or 15 Â 35 cm where appropriate, Korotkoff phase V for diastolic BP). Measurements were taken by physicians who fulfilled the British Hypertension Society Protocol criteria for observer agreement in BP measurement. 16 Definitions CRH was defined as average CBP X140/90 mm Hg (systolic and/or diastolic) in two study visits while on stable treatment with X3 antihypertensive drugs for X4 weeks. TRH was defined as average awake ABP (reference method) X135/85 mm Hg while on stable treatment with X3 antihypertensive drugs for X4 weeks.
Analysis
Participants who provided o12 valid HBP readings were excluded. HBP readings that were more than 50% higher than the next highest HBP reading of the individual subject were considered erroneous and were discarded, as were measurements with systolic BP o60 mm Hg or 4250 mm Hg and those with diastolic BP o30 mm Hg or 4150 mm Hg. All HBP readings were averaged to give a single number per individual.
ABP data and additional recorded information from the report files generated by the ambulatory monitors were batch imported and organized in a relational database (Microsoft-Access 2000) using a visual basic program. This program designed by LGR for statistical analysis of ABP-derived data reads the ASCII text files generated by the ABP monitor and performs multiple data procedures and analyses, including flagging erroneous readings, valid readings and duplicate readings (repeats), and calculates the average awake ABP according to each individual's in-bed and out-of-bed periods. ABP recordings with o20 valid awake readings were excluded. Early readings taken o20 min after the monitor had been attached to subjects were also excluded because these had been taken in the clinic. The average of the second and third CBP readings of the first two study visits (four readings) was calculated to obtain the CBP per individual.
The diagnostic ability of HBP (sensitivity, specificity, and positive and negative predictive values) to detect: (i) RH and white coat phenomenon among subjects with elevated CBP on stable treatment with X3 antihypertensive drugs and (ii) TRH and masked RH among those on stable treatment with X3 antihypertensive drugs was assessed by taking awake ABP as reference method. Threshold for hypertension diagnosis was X135/85 mm Hg (systolic and/or diastolic) for HBP and awake ABP, and X140/90 mm Hg for CBP. A sensitivity analysis for the diagnosis of CRH was also performed using as reference value the 24-h ABP threshold of 130/80 mm Hg.
Student's paired t-test was used for the comparison of BP measurements in the same subjects with Bonferroni's correction for multiple comparisons applied where appropriate. Student's unpaired t test was used to compare values among subgroup of participants. The kappa statistic was used to determine the level of agreement in diagnoses made by ABP and HBP. A probability value Po0.05 was considered statistically significant. Statistical analysis was performed using the PASW 18 (SPSS release 18.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Demographics
A total of 710 subjects have been assessed by the three BP measurement methods and 613 (86%) had complete CBP, ABP and HBP data. Among the 613 subjects, 73 (12%) were on stable treatment with X3 drugs, 44 were classified as having CRH (mean age 62±11 years, 59% male, BMI 28±3.5 kgm
À2
) and 40 as having TRH (mean age 60 ± 10 years, 70% male, BMI 29 ± 3.8 kgm À2 , P ¼ NS (not significant) for all comparisons versus the CRH group). The average number of drugs received was 3.5 ± 0.6 (range 3 --5; 93% on diuretics) in subjects with CRH and 3.5 ± 0.6 (range 3 --5; 90% on diuretics) is those with TRH (P ¼ NS).
BP measurements
In CRH subjects average CBP (152 ± 12/86 ± 12 mm Hg, systolic/ diastolic) was higher than HBP (144 ± 15/81 ± 12 mm Hg, Po0.001) and awake ABP (138 ± 13/80 ± 11 mm Hg, Po0.001), whereas systolic HBP was higher than awake ABP (Po0.01, Figure 1 ). Significant associations were found between awake ABP and HBP measurements (correlation coefficient r for systolic/diastolic 0.52/ 0.85, Po0.001 for both). In TRH patients there were no differences among CBP (146±17/85±12 mm Hg), HBP (146±14/83±9 mm Hg) and awake ABP (144 ± 9/84 ± 11 mm Hg, Figure 1) , and the correlation coefficient r between awake ABP and HBP was 0.36/ 0.79, Po0.05/0.01, for systolic/diastolic. No difference in CBP or HBP was found between the CRH and TRH groups, whereas systolic awake ABP was higher in the latter group (mean difference 6.3 ± 2.4/3.9 ± 2.4 mm Hg, Po0.05/NS, Figure 1 ).
Diagnostic evaluation
Among 44 CRH subjects, RH was confirmed by awake ABP in 28 (64%) and by HBP in 32 (73%) (P ¼ NS). Both awake ABP and HBP confirmed RH in 26 subjects (59%) and none in 10 (23%) (agreement in 82%, kappa 0.59). In 2 subjects (5%) CRH was confirmed by awake ABP but not by HBP and in 6 subjects (14%) the reverse. For individual subjects with disagreement in the diagnosis of CRH (systolic and/or diastolic), the BP deviations of HBP and awake ABP away from the diagnostic threshold are presented in Figure 2 . Two out of these eight patients had both systolic and diastolic disagreement (Figure 2 ). In four out of these eight cases the deviation above the threshold for HBP or awake ABP was o5 mm Hg (Figure 2) , which was not regarded as clinically important. The sensitivity, specificity, and positive and negative predictive values of HBP in detecting CRH by taking awake ABP as reference method are presented in Table 1 . Comparable yet lower were the sensitivity, specificity, and positive and negative predictive values (92%, 56%, and 75% and 83%, respectively) and the diagnostic agreement 77% (kappa 0.51, Po0.001) when 24-h ABP was used as reference method.
Among subjects on X3 antihypertensive drugs (n ¼ 73), the proportion of those with white coat phenomenon (elevated CBP and low out-of-clinic BP) assessed by ABP or HBP monitoring is presented in Figure 3 . Among subjects with CRH, white coat phenomenon was diagnosed in 16 (36%) using ABP and in 12 (27%) using HBP (agreement in 82%, kappa 0.59). The sensitivity, specificity, and positive and negative predictive values of HBP compared with those of awake ABP in diagnosing the white coat phenomenon among subjects with CRH are presented in Table 1 .
Among 73 subjects on X3 antihypertensive drugs, 40 (55%) had TRH (based on ABP monitoring) and 51 (70%) had TRH based on HBP monitoring (P ¼ NS) (Figure 3 ). There was agreement between HBP and awake ABP in the diagnosis of TRH in 54 subjects (74%, kappa 0.46; 36 (49%) confirmed by both and 18 (25%) excluded by both). In 4 subjects (5%) TRH was confirmed by awake ABP but not by HBP and in 15 subjects (21%) the reverse. In 10 out of these 19 cases the BP disagreement was not regarded as clinically important (deviation of elevated HBP or awake ABP above the diagnostic threshold o5 mm Hg). The sensitivity, specificity, and positive and negative predictive values of HBP compared with that of awake ABP in detecting TRH are presented in Table 1 .
The prevalence of masked RH (low CBP and elevated out-ofclinic BP) detected by ABP or HBP monitoring among subjects on X3 antihypertensive drugs is also presented in Figure 3 . Masked RH was diagnosed in 12 subjects (16%) with awake ABP and 19 subjects (26%) with HBP (P ¼ NS). Masked RH was confirmed by both ABP and HBP in 10 subjects (14%) and by none in 52 (71%) (agreement in 85%, kappa 0.56). In two subjects (3%) masked RH was confirmed by ABP but not HBP and in 9 subjects (12%) the reverse. The sensitivity, specificity, and positive and negative predictive values of HBP compared with that of awake ABP in detecting masked RH are presented in Table 1 .
DISCUSSION
This study assessed the usefulness of HBP as compared with ABP monitoring in confirming the diagnosis of RH. The issues of TRH, the white coat and masked hypertension phenomena among subjects on triple drug therapy have also been investigated. The main finding of the study is that there is 71 --82% agreement between HBP and ABP monitoring in confirming the diagnosis of RH and the white coat phenomenon among subjects with CRH, and of TRH and masked RH hypertension among subjects on triple therapy. Furthermore, in about half of the cases with diagnostic disagreement between ABP and HBP, the deviation of the BP values (home or ambulatory) away from the diagnostic threshold was not considered as clinically important (o5 mm Hg), because such a small difference above the diagnostic threshold will probably be considered by the physician as uncertain to decide treatment titration because of the random BP variability.
Diagnostic value of HBP A recent systematic review has identified 16 trials that investigated the diagnostic performance of HBP by taking ABP as reference method. 9 In these studies, the diagnostic ability of HBP was tested in untreated or treated subjects aiming to detect sustained hypertension, and the white coat and masked hypertension phenomena. Comparison of these data with the findings reported in this paper in terms of sensitivity, specificity, predictive and kappa values suggest that HBP is at least as reliable diagnostic method in the setting of RH as it is in the usual population of untreated on treated hypertensives. 9 In the MEDIT --HABP collaborative study of 1441 subjects from Greece, Italy and Spain there was agreement between ABP and HBP in diagnosing sustained hypertension in 86% of the cases, white coat hypertension in 86% and masked hypertension in 89%. 17 By taking ABP as the reference method, the sensitivity, specificity, and positive and negative predictive values of HBP in detecting sustained hypertension were 88%, 85%, and 83% and 90%, respectively, white coat hypertension were 55%, 93%, and 66% and 90%, respectively, and masked hypertension were 57%, 93%, and 50% and 95%, respectively. 17 Given that the diagnostic disagreement between ABP and HBP can be attributed, at least in part, to their imperfect reproducibility, 18 these findings suggest that these two methods might be regarded as interchangeable in the diagnosis of hypertension.
ABP monitoring in RH The diagnostic and prognostic values of ABP in RH have been assessed in several previous studies. 2, 5 In a study of 286 patients classified as resistant hypertensives (elevated CBP on at least three antihypertensive drugs), ABP monitoring confirmed true resistance to treatment in 56%, whereas the remaining 44% had the white coat phenomenon. 19 In a more recent study by Oliveras et al. 20 in 143 patients with clinic RH, ABP monitoring confirmed RH in 72%, whereas 28% had white coat hypertension. These data are in line with the present study findings showing that despite the careful assessment of CBP in two study visits and after one pre-study visit more than one-third of subjects with CRH (36%) had low ABP (Figure 3) . Another study by Muxfeldt et al. 21 in 497 patients with RH in the clinic showed that those with elevated ABP (63%) had more severe target-organ damage (microalbuminuria and left ventricular hypertrophy) than those with low ABP. Redon et al.
2 investigated the prognostic value of ABP compared with that of CBP in 86 subjects with RH in the clinic followed for 4 years and showed that subjects at the top tertile of ABP values had the worst cardiovascular prognosis. Another study by Pierdomenico et al., 22 in 276 patients with apparently RH in the clinic, those with false RH (low ABP) were at lower risk of cardiovascular events than those with TRH (high ABP) .
HBP monitoring in RH Scarce data are available on the diagnostic and the prognostic values of HBP monitoring in the patients with RH. The diagnostic value of HBP monitoring in RH has been evaluated in the J-Home study. 23 In this study, 528 hypertensive subjects taking at least three antihypertensive drugs were assessed by CBP and HBP, and 16.1% were detected with isolated clinic (white coat) RH, 23.5% with isolated home (masked) RH and 42.6% with sustained (in and out of clinic) RH. Because of different populations being included and other methodological differences (for example, number of HBP readings) these data are not directly comparable with the present study. However, both studies underscore the role of HBP monitoring in the evaluation of RH and the common diagnostic misclassification if only conventional CBP measurements are performed.
Masked resistant hypertension
An important issue demonstrated in the present study is that, further to the need of out-of-office BP assessment in all subjects with CRH in order to identify those with white coat phenomenon (more than one-third), all subjects with low CBP on triple drug therapy require out-of-office BP assessment to identify the masked hypertension phenomenon (about 20%) (Figure 3) . In other words, all hypertensives on triple drug therapy require evaluation of out-of-office BP, irrespective of the level of their CBP (elevated or low). By basing treatment decisions exclusively on CBP measurements, about half of the patients will not receive the appropriate therapy but will be either overtreated because of white coat hypertension or undertreated because of masked hypertension phenomenon (Figure 3) . Such a wide application of out-of-office BP assessment in treated hypertensives for general application can only be achieved by HBP monitoring, because of its low cost, wide availability and good patients' acceptance. 8 ABP vs HBP monitoring in RH To our knowledge, a single study from Brazil performed ABP and HBP monitoring in patients with RH. 24 This study in 51 patients reported a close association between daytime ABP and HBP (correlation coefficient, r, 0.70/0.69 for systolic/diastolic compared with 0.52/0.85 in the present study), and showed that ABP confirmed RH in 33 subjects and HBP in 37 (P ¼ NS), whereas 18 and 14 subjects had white coat phenomenon detected by ABP and HBP, respectively. 24 These data are in accord with the present study findings, yet the diagnostic ability of the two methods (sensitivity, specificity and so on) has not been investigated.
The relatively small number of RH patients (n ¼ 73) and the lack of assessment of the association of the BP measurement methods with indices of target-organ damage and/or risk of cardiovascular events might be considered as the main limitations of the current study. It might be argued that the previous use of HBP monitoring might affect the diagnostic value of HBP compared with that of ABP. However, this issue was not investigated in this study because information of previous use of HBP monitoring by the study participants was not available.
CONCLUSION
There is substantial agreement of HBP with ABP monitoring in confirming the diagnosis of RH and in detecting the white coat phenomenon and masked RH among hypertensive subjects on triple drug therapy. Given the low cost, the wide availability and the good acceptance of HBP monitoring by patients, this method appears to be a valuable tool for the evaluation of treated hypertension on multiple drug therapy. The high prevalence of the white coat phenomenon among subjects with CRH and also of the masked hypertension phenomenon among subjects with low CBP on triple drug therapy suggest that HBP monitoring should be mandatory in the evaluation of all hypertensive patients receiving multiple drug therapy, irrespective of the level of CBP. In conclusion, this study provides the first evidence that HBP monitoring is a reliable alternative to ABP monitoring in the evaluation of RH. Larger studies are needed to confirm these data and also to investigate the relationship of the measurement methods with target-organ damage and cardiovascular risk in patients with RH.
What is known about this topic
Ambulatory blood pressure monitoring is recommended as a standard method for the evaluation of resistant hypertension. White coat and masked hypertension phenomenon is at least as common as among general hypertensive subjects. Scarce data are available regarding the diagnostic value of home blood pressure monitoring in patients with resistant hypertension.
What this study adds
There is substantial agreement of home with ambulatory blood pressure monitoring in confirming the diagnosis of resistant hypertension and in detecting the white coat phenomenon and masked resistant hypertension among hypertensive subjects on triple drug therapy. These methods are necessary in both uncontrolled and controlled subjects on triple therapy to detect the white coat phenomenon and masked resistant hypertension.
